ALISO VIEJO, Calif.--(BUSINESS WIRE)--GE Healthcare announced today that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma. As part of these upgrades, a new service known as PATHSiTE™ Virtual HemeFISH (VHF), will be offered as an integrated component of the web-based case management portal. PATHSiTE VHF will help pathologists to better interpret, diagnose and report on suspected blood cancers and disorders.
Help employers find you! Check out all the jobs and post your resume.
